The Management of Co-Morbidities in Patients with Heart Failure – Obstructive Sleep Apnoea

Andrew Coats

Abstract


Heart failure (HF) patients are older and frequently present with multiple co-morbidities. Co- morbidities worsen patient symptoms and may contribute to the progression of heart failure, increase mortality or limit the therapeutic response to treatment. Obstructive sleep apnoea (OSA) affects 2–4% of the adult population world-wide and is associated with similar risk factors to HF, meaning it is a frequent finding in HF patients, including HFrEF, HFmrEF and HFpEF. OSA has consistently been shown to be associated with hypertension, coronary artery disease, arrhythmias, heart failure, and stroke. A thorough understanding of the diagnosis and treatment options of OSA is of paramount importance to the practising HF clinician. Patients may present to the HF specialist having been diagnosed by a formal sleep study or may be suspected of OSA because of symptoms of snoring, reports of obstructed breathing by the sleep partner or day-time sleepiness. The mainstay of treatment for OSA is a positive airway pressure mask which can be used in mild moderate and severe OSA. The need for therapy should be discussed with the patient and if the AHI is above 15/hr then treatment is indicated to reduce this to below 15. This is a consensus recommendation and no adequately powered clinical trials have shown this improves either mortality or the risk of disease progression. Other options are discussed

Full Text:

455 HTML

References


Jilek C, Krenn M, Sebah D, et al. Prognostic impact of sleep disordered breathing and its treatment in heart failure: an observational study. Eur J Heart Fail. 13: 68–75, 2011.

Khayat R, Jarjoura D, Porter K, et al. Sleep disordered breathing and post- discharge mortality in patients with acute heart failure. Eur Heart J. 36: 1463–69, 2015.

Coats AJ, Shewan LG. Measuring therapeutic efficacy in the treatment of central sleep apnoea in patients with heart failure. Int J Cardiol. 2016 Mar; 206 Suppl: S16–21. doi:10.1016/j.ijcard.2016.02.123.

Javaheri S: A mechanism of central sleep apnea in patients with heart failure. N Engl J Med. 341: 949–54, 1999.

Khoo MC, Kronauer RE, Strohl KP, et al. Factors inducing periodic breathing in humans: a general model. J Appl Physiol. 53: 644–59, 1982.

Bitter T, Westerheide N, Prinz C, et al. Cheyne- Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter- defibrillator therapies in patients with congestive heart failure. Eur Heart J. 32: 61–74, 2011.

Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation scientific statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. Circulation. 118: 1080–1111, 2008.

Epstein LJ, Kristo D, Strollo PJ Jr, et al. Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long- term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009 Jun 15; 5(3): 263–76.

El Shayeb M, Topfer LA, Stafinski T, et al. Diagnostic accuracy of level 3 portable sleep tests versus level 1 polysomnography for sleep- disordered breathing: a systematic review and meta- analysis. CMAJ. 186: E25– E51, 2014.

Shewan LG, Coats AJS, Henein M. Requirements for ethical publishing in biomedical journals. International Cardiovascular Forum Journal 2015;2:2, DOI: 10.17987/icfj.v2i1.4.




DOI: https://doi.org/10.17987/icfj.v10i0.455

Comments on this article

View all comments


Copyright (c) 2017 The Author

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.